IL17A and colitis: Another study performed in mice model of experimental colitis has shown that treatment of colitic mice with EcN_OMVs could reduce intestinal inflammation by inhibiting the expression of IL-1β, TNF-α and IL-17 and enhancing the expression of IL-10 in colonic tissues [39].